The five scientists represent five different academic institutions in Houston. Photo via Getty Images

The National Academy of Inventors has recognized 175 scientists from across the world as NAI Fellows — and five of those inventors are based at Houston institutions.

The program honors academic inventors who, according to NAI, "have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society."

The five Houston inventors join the ranks of a group of individuals who have generated over 13,000 licensed technologies and companies, and created more than 19 million jobs, according to the announcement.

These are the scientists from Houston organizations:

  • Ananth Annapragada of Baylor College of Medicine is professor of radiology and obstetrics and gynecology, vice chief of research and director of basic research at Baylor College of Medicine and Texas Children's Hospital as well as a member of the Dan L Duncan Comprehensive Cancer Center.
  • Ronald Biediger of the Texas Heart Institute is associate director of chemistry, Wafic Said Molecular Cardiology Research Laboratories and leading a group of chemists developing small molecule integrin antagonists and agonists for use as therapies, or as adjuncts to cell based therapies, for heart, lung and vascular disease
  • Mark Clarke of the University of Houston is associate provost for faculty development and faculty affairs at the University of Houston.
  • Ashutosh Sabharwal of Rice University is professor and Ph.D of electrical engineering and was named Fellow of the Institute of Electrical and Electronics Engineers in 2014 for contributions to the theory and experimentation of wireless systems and networks.
  • Jia Zhou of The University of Texas Medical Branch is professor in the Department Pharmacology and Toxicology focusing on drug discovery of bioactive molecules to probe biological systems or act as potential therapeutic agents in neuroscience, cancer/inflammation, infectious diseases, and other human conditions.

The new class of inventors will be inducted on June 8 at the 10th Annual Meeting of the National Academy of Inventors in Tampa, Florida.

These scientists have already established dozens of patents between the five of them across fields and industries. Clarke specifically holds 13 U.S. patents, seven NASA technology innovation awards, and has founded two life science startup companies to commercialize his technologies, according to a news release from UH.

"Most faculty inventors, including myself, do not begin their research careers focused on creating or commercializing new technologies, nor do they usually know where to start when presented with such an opportunity," Clarke says in the release. "Helping faculty members and students transition fundamental discoveries into commercially valuable technologies and products is not only a key part of our mission as a Tier One research university, it is critical to our region's economic prosperity and ensuring that the U.S. remains competitive in an innovation-driven global economy."

From BCM, Annapragada holds 15 patents in the United States and close to 100 worldwide. The majority of his patents are in next generation imaging technologies, CT vascular imaging, and MR molecular imaging, according to a BCM release, and Annapragada is the founder of two active startup companies — Alzeca Inc. and Sensulin LLC.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”